GlassScriptPhysician profile
Amy R Harrell
NPI 1811338767
$5,439.44
in general payments reported to CMS, 2019-2025
46 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,902 · 2022: $1,476 · 2023: $1,980 · 2024: $81.13.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,996 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,996.28 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,400.83 | 2021-2023 | |
| Novo Nordisk INC | $554.07 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $366.19 | 2021-2023 | |
| Lilly USA, LLC | $353.29 | 2021-2023 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $292.15 | 2021-2023 | Farxiga, Breztri |
| Astellas Pharma US INC | $224.23 | 2021-2024 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $224.15 | 2021-2023 | Spiriva Respimat |
| Amgen INC. | $147.72 | 2021-2023 | Prolia, Evenity, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $131.40 | 2022-2023 | |
| Glaxosmithkline, LLC. | $130.42 | 2021-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $126.94 | 2021-2023 | Verquvo, Belsomra |
| Abbott Laboratories | $118.78 | 2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $110.26 | 2021-2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $102.60 | 2021-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $84.76 | 2021-2023 | Rexulti |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Harrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.